Extramedullary multiple myeloma escapes the effect of thalidomide

Haematologica

Volumn 89, Issue 7, 2004, Pages 832-836

  Rosiñol, Laura ^a   Cibeira, Ma Teresa ^a   Bladé, Joan ^a,b   Esteve, Jordi ^a   Aymerich, María ^a   Rozman, María ^a   Segarra, Marta ^a   Cid, Maria C ^a   Filella, Xavier ^a   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Multiple myeloma; Plasmacytomas; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; ATRIOVENTRICULAR BLOCK; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; FACE EDEMA; FATIGUE; FEMALE; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HUMAN; MALE; MULTIPLE MYELOMA; PARESTHESIA; PLASMACYTOMA; RASH; SKIN MANIFESTATION; SOFT TISSUE CANCER; SOMNOLENCE; THROMBOEMBOLISM; TREATMENT OUTCOME; TREMOR;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BONE MARROW NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; SOFT TISSUE NEOPLASMS; THALIDOMIDE;

EID: 3242763046     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting feaures, response to therapy and survival in a series of 53 cases. J Clin Oncol 1994;12:2398-404.
2. Bladé J, Kyle R.A, Greipp PR. Presenting features and prognosis in 72 patients with Multiple myeloma who were younger than 40 years. Br J Haematol 1996;93:345-51.
3. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
4. Singhal S, Metha J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
5. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adrianson M, Malm, C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
6. Kneller A, Raanani P, Hardan A, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an olg drug. Br J Haematol 2000;108:191-3.
7. Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumonter C, et al. Thalidomide in patients with advanced multiple myeloma. Hematology J 2000;1:186-9.
8. Rajkumar S.V, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000;75:897-901.
9. Barlogie B, Desikan R, Eddelmon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
10. Bladé J, Esteve J, Rosiñol L, Perales M, Montoto S, Tuset M, et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001;28:588-92.
11. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL, et al. Response rate, durability of response and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003;78:34-9.
12. Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001;42:683-7.
13. Kumar S, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003;101:1715-7.
14. Bladé J, Perales M, Rosiñol L, Tuset M, Montoto S, Esteve J, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001;13:422-5.
15. Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide in multiple Myeloma. Leuk Lymphoma 2001;42:683-7.
16. Anagnostopoulos A, Hamilos G, Grigoraki V, Dimopoulos MA. Discordant response or progression in patients with refractory myeloma treated with thalidomide based regimens. Hematology J 2003;4 Suppl 1: S236a [abstract].
17. Bladé J, Samson D, Reece D, Apperley J, Gahrton G, Bjorkstrand B, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
18. Kaplan E.L, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola, Iodice G, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995;50:9-14.
20. Ribatti D, Vacca A, Nico B, Quondomatteo F, Ria R, Minischetti M, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Haematol 1999;79:451-5.
21. Vacca A, Ribatti D, Presta M, Minischetti M, Ria R, Albini A, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-73.
22. Sezer O, Niemoller K, Euker J, Jacob C, Kauffmann O, Zavrski J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Haematol 2000;79:574-7.
23. Sezer O, Jacob C, Eucker J, Niemöller K, Gatz F, Werneche KD, et al. Serum levels of the angiogenic cytokines basic fibroblastic growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-8.
24. Seidel C, Lenhof S, Bravrand S, Anderson G, Standal TM, Lang-Nielsen JL, et al. Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. The Nordic Myeloma Study Group. Br J Haematol 2002;119:672-6.
25. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002;116:796-802.
26. Leroche M, Broussett P, Ludot I, Mazières Thiechart M, Attal M. Increased vascularization in myeloma. Eur J Haematol 2001;66:89-93.
27. Podar K, Tai YT, Davies E, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428-35.
28. Lentzsch S, Leblanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodullatory analogs to thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-4.
29. Mitsiades CS, Mitsiades WS, Kung AL, Munshi N, Anderson KC. In vivo mouse models for the development of novel biologically based therapies for MM. Hematol J. 2003;4 Suppl 1:S50-S1.
30. Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodullatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
31. Richardson PG, Barlogie B, Berenson J, et al. A phase II study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
32. Anderson KC. Targetet therapy for multiple myeloma. Semin Haematol 2001;38:286-94.